Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B12

Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B12 ORIGINAL CONTRIBUTION Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B Marta Ebbing, MD Context Recently, concern has been raised about the safety of folic acid, particu- larly in relation to cancer risk. Kaare Harald Bønaa, MD, PhD Ottar Nyga ˚ rd, MD, PhD Objective To evaluate effects of treatment with B vitamins on cancer outcomes and all-cause mortality in 2 randomized controlled trials. Egil Arnesen, MD Design, Setting, and Participants Combined analysis and extended follow-up Per Magne Ueland, MD, PhD of participants from 2 randomized, double-blind, placebo-controlled clinical trials (Nor- Jan Erik Nordrehaug, MD, PhD wegian Vitamin Trial and Western Norway B Vitamin Intervention Trial). A total of 6837 patients with ischemic heart disease were treated with B vitamins or placebo be- Knut Rasmussen, MD, PhD tween 1998 and 2005, and were followed up through December 31, 2007. Inger Njølstad, MD, PhD Interventions Oral treatment with folic acid (0.8 mg/d) plus vitamin B (0.4 mg/d) Helga Refsum, MD, PhD and vitamin B (40 mg/d) (n=1708); folic acid (0.8 mg/d) plus vitamin B (0.4 mg/d) 6 12 (n=1703); vitamin B alone (40 mg/d) (n=1705); or placebo (n=1721). Dennis W. Nilsen, MD, PhD 6 Main Outcome Measures http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Loading next page...
 
/lp/american-medical-association/cancer-incidence-and-mortality-after-treatment-with-folic-acid-and-rbwn8CAVHr
Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2009.1622
pmid
19920236
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B Marta Ebbing, MD Context Recently, concern has been raised about the safety of folic acid, particu- larly in relation to cancer risk. Kaare Harald Bønaa, MD, PhD Ottar Nyga ˚ rd, MD, PhD Objective To evaluate effects of treatment with B vitamins on cancer outcomes and all-cause mortality in 2 randomized controlled trials. Egil Arnesen, MD Design, Setting, and Participants Combined analysis and extended follow-up Per Magne Ueland, MD, PhD of participants from 2 randomized, double-blind, placebo-controlled clinical trials (Nor- Jan Erik Nordrehaug, MD, PhD wegian Vitamin Trial and Western Norway B Vitamin Intervention Trial). A total of 6837 patients with ischemic heart disease were treated with B vitamins or placebo be- Knut Rasmussen, MD, PhD tween 1998 and 2005, and were followed up through December 31, 2007. Inger Njølstad, MD, PhD Interventions Oral treatment with folic acid (0.8 mg/d) plus vitamin B (0.4 mg/d) Helga Refsum, MD, PhD and vitamin B (40 mg/d) (n=1708); folic acid (0.8 mg/d) plus vitamin B (0.4 mg/d) 6 12 (n=1703); vitamin B alone (40 mg/d) (n=1705); or placebo (n=1721). Dennis W. Nilsen, MD, PhD 6 Main Outcome Measures

Journal

JAMAAmerican Medical Association

Published: Nov 18, 2009

References